All lobbying filings

TIBER CREEK GROUP

Lobbying for AMGEN INC

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 19, 2026

Official filing document

Bills named in this filing 2

HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.

Health Issues

Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.